Analysis
Merck’s $6 Billion Cancer Power Move: The Terns Pharma Deal That Rewrites Pharma’s Post-Keytruda Playbook
Merck nears a $6bn all-cash acquisition of Terns Pharma and its CML drug TERN-701. Here’s the full strategic picture—what it means for patients, investors, and Big Pharma’s 2026 M&A wave.
The ink isn’t dry. The deal isn’t signed. But the logic behind Merck’s reported $6 billion pursuit of Terns Pharmaceuticals is already one of the clearest strategic narratives in modern pharma — a $30 billion time bomb called Keytruda, and the urgent search for what comes after.
Merck is nearing a roughly $6 billion all-cash deal to acquire Terns Pharmaceuticals, the Financial Times reported on Tuesday, citing people familiar with the matter. MarketScreener Talks between the two companies are at an advanced stage, and a deal could be reached within days. MarketScreener The target: a Foster City, California clinical-stage company whose lead drug is quietly generating the most excitement in blood cancer treatment since a Novartis blockbuster redrew the CML landscape a generation ago.
For Merck, this is not merely another acquisition. It is an act of strategic triage — and perhaps the most scientifically precise bet the Kenilworth giant has placed since it licensed pembrolizumab from Schering-Plough in 2009 and renamed it Keytruda.
Why Keytruda’s Patent Cliff Is the Most Watched Clock in Global Pharma
To understand why Merck is willing to pay a premium for a drug that has never been approved — and has barely cleared Phase 1 — you must first understand the existential arithmetic of the world’s best-selling medicine.
Keytruda is slated for a loss of exclusivity in 2028, and a growing pipeline of biosimilars is already lining up to take a shot at the drug’s massive market. Fierce Pharma The cancer therapy brought the company $29.5 billion last year C&EN, representing nearly half of Merck’s total revenue. CEO Robert Davis sees about $70 billion in commercial opportunities by the mid-2030s and has described the current pipeline as one of the “deepest and broadest” Merck has ever had. Stocktwits
That confidence, however, must be earned — deal by deal, trial by trial. Merck has predicted Keytruda will collect $35 billion in peak annual sales in 2028, the same year the drug will face an expected patent cliff. Fierce Pharma After that, biosimilar entrants from Samsung Bioepis, Amgen, and Indian manufacturers are expected to erode revenues precipitously. The company needs successors, and it needs them now.
The response has been an M&A blitz of rare intensity. Merck has accelerated dealmaking in recent months, snapping up Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion last year Investing.com, adding a first-in-class COPD therapy and a long-acting flu antiviral, respectively. Merck has been building up its late-stage drug pipeline since 2021 and has signed several deals to broaden its portfolio. U.S. News & World Report February brought yet another structural bet: Merck split its core pharmaceutical business in two — one housing its oncology portfolio and the other including all non-cancer medicines Fierce Pharma — a move analysts interpreted as pre-positioning for either a spin-off, a focused acquisition strategy, or both.
The Terns deal, if confirmed, is the latest and sharpest arrow in that quiver.
TERN-701: The Drug That Has CML Specialists Talking in Superlatives
Chronic myeloid leukemia is not a common cancer. Roughly 8,900 new cases are diagnosed in the United States each year. But it is a high-value market — heavily treated with expensive precision medicines — and Terns has built its entire identity around the conviction that the next generation of CML therapy remains conspicuously unfinished.
Terns’ lead cancer drug candidate is TERN-701, which is in development for the treatment of relapsed/refractory CML under the Phase 1 CARDINAL trial. RTTNews The drug’s mechanism is where the science gets genuinely interesting: TERN-701 is active at the myristate pocket of BCR-ABL1, providing it with 10,000 times greater selectivity than active-site tyrosine kinase inhibitors. Onclive
That molecular precision matters enormously in a disease defined by acquired resistance. The current standard of care for later-line CML, Novartis’s asciminib (Scemblix), was itself an allosteric BCR-ABL inhibitor that redrew treatment algorithms when it won approval — but resistance mutations and tolerability issues mean a significant portion of patients still cycle through therapies without achieving durable molecular response. Early study results suggest that TERN-701 could be a successor to Novartis’s blockbuster Scemblix. Statnews
The CARDINAL trial data, presented at the American Society of Hematology annual meeting in December 2025, was what turned heads. At the recommended Phase 2 dose of at least 320 mg once daily, the overall 24-week major molecular response rate was 80% among efficacy-evaluable patients with more than 24 weeks of follow-up. Onclive For patients maintaining MMR, the rate held at 100%. Ternspharma
The safety profile is equally notable. The majority of treatment-emergent adverse effects were low grade, with no apparent dose relationship. Rates of cytopenias were generally low, with less than 10% Grade 3 thrombocytopenia and neutropenia. Onclive No dose-limiting toxicities were observed up to the maximum dose of 500mg QD. Ternspharma
For heavily pre-treated patients — many of whom had previously received asciminib, ponatinib, and investigational next-generation therapies — these numbers are not merely encouraging. They are, by the standards of relapsed/refractory CML, remarkable. “Best-in-disease potential” is the phrase Terns itself has used, and the clinical data does not obviously contradict that claim.
The Valuation Calculus: What Does $6 Billion Actually Buy?
The all-cash deal is expected to value Terns at a premium to its market capitalization of about $5.3 billion. Investing.com That premium, while meaningful, is modest by the standards of 2025–2026 oncology M&A — a sector where bidding wars routinely push acquirers to 60–80% above last close.
Why the relative restraint? Several factors shape the math.
TERN-701 remains in Phase 1. There is no approved product, no commercial infrastructure, and no Phase 3 data. Pivotal trial results — the evidence that would trigger blockbuster valuations and genuine upside scenarios — are still at least two to three years away. For a drug targeting a relatively rare indication, the peak revenue ceiling, while lucrative, is bounded. Analysts covering the CML market typically model mature annual sales for a best-in-class next-generation allosteric inhibitor in the $2–4 billion range globally, depending on label breadth and first-line expansion.
At $6 billion all-cash, Merck is effectively paying two to three times peak sales estimates upfront — aggressive, but not irrational when the acquirer is running a multi-decade oncology platform and values de-risked, validated science over raw market speculation.
The deal also reflects Terns’ strategic leverage. Terns had cash runway into 2028 focused on advancing the CML program internally and partnering metabolic assets Ternspharma — meaning the company was not under existential financial pressure to sell. That negotiating position, combined with competitive interest from other potential suitors, likely shaped the final price.
The Broader Strategic Picture: Merck’s New Oncology Architecture
The Terns acquisition, viewed in isolation, reads as a sensible pipeline bolt-on. Viewed in the context of Merck’s full strategic reshaping, it takes on a different quality — the latest piece in what is becoming one of the most ambitious pharma rebuilding exercises since the post-Lipitor era.
Consider the deal sequencing. Merck’s $11.5 billion deal for Acceleron Pharmaceuticals added the pulmonary arterial hypertension therapy Winrevair; the Verona Pharma acquisition brought Ohtuvayre, a first-in-class COPD treatment; and the Cidara deal added CD388, a long-acting antiviral against all flu strains. Invezz Each transaction has shared a common logic: early enough in commercial life to offer genuine upside, but far enough along in clinical development to substantially de-risk.
TERN-701 fits that template — though the clinical-stage risk is somewhat higher than in those prior deals. What elevates the strategic rationale is the oncology division context. As part of the restructuring, Merck’s human-health business will be split into two — one housing its oncology portfolio and the other including all of its non-cancer medicines. U.S. News & World Report Citi analysts said the split would help to more clearly distinguish Merck’s mature oncology portfolio from its newer, acquisition-driven assets. U.S. News & World Report
Adding a potentially best-in-class CML asset directly strengthens the new oncology unit’s pipeline depth — a consideration that matters not only commercially, but also in how investors and potential partners value the separated entity. If Merck eventually pursues a spin-off or strategic transaction involving the oncology division, a richer pipeline commands a materially higher multiple.
There is also the question of platform. BCR-ABL inhibition in CML has historically served as a scientific and regulatory template for targeted therapies in adjacent hematological malignancies. If TERN-701’s allosteric mechanism proves transferable — to blast phase CML, to Philadelphia chromosome-positive ALL, or to other BCR-ABL-driven contexts — the addressable market expands substantially beyond the initial rare indication.
What It Means for Patients: Access, Pricing, and the CML Treatment Gap
Abstract strategy and valuation calculus exist in tension with a more human question: what does this deal mean for the roughly 30,000 Americans — and hundreds of thousands globally — currently living with CML?
On balance, consolidation under a well-capitalized major pharma is likely to accelerate the path to approval. Merck’s regulatory infrastructure, commercial relationships, and Phase 3 execution capability represent genuine accelerants for a drug that Terns, as a clinical-stage company, would have struggled to advance at comparable speed. The CARDINAL trial needs to expand into a full pivotal program; a major pharma’s resources materially compress that timeline.
The pricing question is less comfortable. Tyrosine kinase inhibitors for CML are already among the most expensive chronic disease therapies in the U.S. market. Novartis’s asciminib lists at over $200,000 annually. Should TERN-701 achieve approval — and the Phase 1 data suggests it is on track to try — it will enter a market where Merck will be under both commercial pressure to recoup its $6 billion investment and political pressure to justify the cost of a rare disease therapy.
The international access picture is sharper still. Keytruda may face “price setting” from the Inflation Reduction Act in 2026 C&EN, and the broader U.S.-China oncology R&D race is intensifying as Chinese biotechs, many partnered with or competing directly against Western majors, rapidly advance their own BCR-ABL and kinase inhibitor portfolios. A Merck-owned TERN-701 will need a global commercialization strategy that balances pricing sustainability in the U.S. against access in markets where affordability remains the defining constraint.
The 2026 M&A Wave: Terns as Precedent, Not Outlier
Industry-watchers have spent the past 18 months watching the pharma M&A pipeline with unusual intensity, and the Terns deal — if it closes — will not be the last deal of this kind in 2026. The conditions for a sustained acquisition wave remain firmly in place.
Patent cliffs are not unique to Merck. AstraZeneca, Bristol-Myers Squibb, and Pfizer all face meaningful revenue transitions in the latter half of the decade. Interest rates, while elevated versus the zero-rate era, remain manageable for investment-grade acquirers with strong cash generation. Biotech valuations, while partially recovered from the 2022–2023 trough, have not returned to the frothy heights that previously priced out strategic acquirers. That creates a window — perhaps 18 to 36 months — in which well-capitalized majors can acquire genuine clinical-stage innovation at multiples that may look cheap in retrospect.
The calculus changes if clinical-stage failures mount, or if the regulatory environment shifts adversely for rare oncology indications. But for now, the structural incentives point toward more deals, not fewer. Merck CEO Robert Davis said as much in February: “Our belief in our ability to have substantial growth once we get closer to the [loss of exclusivity] is as high as it’s ever been. And we’re not done.” Fierce Pharma
The Terns deal, at $6 billion, is arguably modest by the ambitions of that statement — a targeted bet on a validated mechanism in a well-understood disease, dressed in the clinical data that Big Pharma acquirers find most legible. What comes next in Merck’s dealmaking could be considerably larger.
Forward Scenarios: Three Possible Outcomes for TERN-701
Scenario 1 — Accelerated Approval Pathway: If TERN-701’s Phase 1 data is persuasive enough for Breakthrough Therapy Designation (which Terns has not yet obtained), Merck could potentially pursue an accelerated approval pathway using MMR as a surrogate endpoint — a strategy previously used for asciminib. A 2028–2029 approval timeline is not implausible. In this scenario, the deal looks like sharp value creation.
Scenario 2 — Pivotal Trial Success, Standard Path: The more likely route involves a full Phase 3 randomized controlled trial, standard FDA review, and approval in the early 2030s. In this scenario, TERN-701 becomes a useful but not transformative contributor to Merck’s oncology revenue — meaningful for patients, positive but not game-changing for Merck’s post-Keytruda financials.
Scenario 3 — First-Line Expansion: The real prize — the scenario that would vindicate the $6 billion price tag in full — is if TERN-701 demonstrates superiority or equivalence to standard-of-care in earlier lines of CML therapy. A first- or second-line label would multiply the addressable patient population by an order of magnitude, transforming a rare disease asset into a genuine oncology pillar.
The Bottom Line
The Merck–Terns deal is not, by the standards of 2025–2026 Big Pharma dealmaking, extraordinary in size. What makes it significant is its specificity. Merck is not buying a diversified biotech platform or hedging its bets across a sprawling pipeline. It is making a concentrated, scientifically defensible wager on one drug, one mechanism, and one disease — a bet that a next-generation allosteric BCR-ABL inhibitor with 80% major molecular response rates in heavily pre-treated patients represents exactly the kind of targeted, data-driven oncology innovation that commands a premium in any market cycle.
Whether TERN-701 ultimately delivers on its early clinical promise remains genuinely uncertain. Phase 1 data, however spectacular, does not guarantee Phase 3 success. Regulatory hurdles, competitive pressure from asciminib and emerging Chinese generics, and the perennial challenges of rare disease commercialization will all shape the eventual story.
But for the patients cycling through failed CML therapies — people who have exhausted three, four, even six prior tyrosine kinase inhibitors — the prospect of a new mechanism with a favorable safety profile and compelling molecular response rates is not a valuation abstraction. It is the news they have been waiting for.
Merck is betting $6 billion on the proposition that those patients deserve a better option. That, at its core, is the deal.
Key Deal Facts at a Glance
- Deal Value: ~$6 billion, all-cash
- Target: Terns Pharmaceuticals (NASDAQ: TERN), Foster City, CA
- Lead Asset: TERN-701 — oral, allosteric BCR-ABL inhibitor for relapsed/refractory CML
- Clinical Stage: Phase 1 CARDINAL trial (dose expansion ongoing)
- Key Clinical Data: 80% MMR rate at ≥320mg dose, 0 dose-limiting toxicities
- Terns Market Cap Pre-Deal: ~$5.3 billion
- Merck’s M&A Spend Since 2024: $25+ billion (Verona Pharma, Cidara, Terns)
- Keytruda Annual Revenue: ~$30 billion; LOE expected 2028
- Deal Status: Advanced negotiations; expected to close within days
Sources: Financial Times, Reuters, Fierce Pharma, Terns Pharmaceuticals IR, ASH 2025 oral presentation (Blood, 2025;146:901), OncLive, Seeking Alpha, STAT News
Discover more from The Economy
Subscribe to get the latest posts sent to your email.
AI
AI Memory Chip Shortage 2026: Nvidia, Apple & What Comes Next
A global memory chip shortage is hitting AI hyperscalers, tanking Nvidia and Apple shares, and triggering a Wall Street rotation. Here’s what the AI sector’s supply crisis means for investors.The artificial intelligence boom that has driven Wall Street’s most extraordinary bull run in a generation is running headlong into a physical constraint: the world cannot produce memory chips fast enough to feed it.
On Friday, June 26, 2026, technology stocks extended a brutal weekly decline even as the broader market stabilized and advancing shares outnumbered declining ones. Nvidia slipped another 1% in early trading and was on pace for an 8% weekly loss—its worst five-day stretch in more than a year. Apple dived after announcing price increases for several iPad and Mac models, citing higher costs from memory chip shortages. Oracle and CoreWeave fell after the New York Times reported that OpenAI was considering delaying its initial public offering to as late as 2027.
What the headlines share is a single underlying cause: the cost of the memory chips that power AI infrastructure is rising faster than even the most aggressive hyperscaler budgets assumed, and the shortage driving that cost increase is not expected to ease before 2028.
The Architecture of the Crisis
Memory chips—specifically the high-bandwidth memory, or HBM, used in AI accelerators—are produced by a small number of manufacturers: SK Hynix, Micron, and Samsung. Demand for HBM has exploded because each new generation of Nvidia’s AI chips requires substantially more of it. As Nvidia pushes its product cycle faster to maintain competitive advantage, each cycle pulls forward enormous new demand for chips that take 18 to 24 months to ramp in production.
Micron reported strong quarterly earnings—its results have been spectacular—but the very strength of those results is the problem for the rest of the tech sector. Micron’s margins are rising because memory is scarce and expensive. The companies buying that memory—Microsoft, Amazon, Alphabet, Meta, and the rest of the hyperscaler complex—are absorbing higher input costs on a scale that is beginning to show up in margin guidance.
Analysts at Charles Schwab noted a “growing wedge” in the technology sector between memory producers like Micron—which is posting massive gains—and the hyperscaler stocks that are watching their AI infrastructure economics deteriorate. The latter group includes names like Microsoft, Amazon, and Alphabet, which are collectively projected to spend between $660 billion and $700 billion on AI infrastructure in 2026, according to research from Fair Observer.
Nvidia’s Problem Is a Market Concentration Problem
Nvidia entered 2026 having crossed a $5 trillion market capitalization—larger by GDP comparison than all but four national economies. That concentration made the stock not merely a bet on AI but a systemic weight in the S&P 500. Nvidia and its mega-cap technology peers now account for roughly 30% of the entire index—the highest concentration in half a century.
When Nvidia corrects, it does not correct in isolation. It reprices the risk premium of every fund manager with an S&P 500 benchmark, which is nearly every institutional investor in the world. The 8% weekly decline in late June—attributed to a combination of rising memory costs, margin anxiety among hyperscaler customers, and a broader rotation away from high-multiple AI stocks—had ripple effects across semiconductor infrastructure names including Lumentum, Marvell Technology, and Corning.
Apple Raises Prices—and Reveals the Exposure
Apple’s announcement of price increases for iPad and Mac models was notable for two reasons. First, Apple’s supply chain is among the most sophisticated on earth; if Apple could not absorb memory cost increases without raising consumer prices, the margin pressure is acute. Second, Apple’s pricing decision revealed an exposure that consumer electronics companies had managed to keep largely invisible through inventory buffers.
Those buffers, built up when memory was cheap, are now depleted. The shortage is forecast to persist through 2027 and potentially into 2028, driven by Nvidia’s accelerated chip release cadence and the insatiable demand of AI data centers for high-bandwidth memory. Analysts at Briefing.com noted that higher memory costs are seen “persisting throughout 2027 and perhaps into 2028, driven by increasing data center demand and Nvidia’s rapid introduction of updated AI chips.”
OpenAI Delays Its IPO—Absorbing the Lesson From SpaceX
The reported delay in OpenAI’s public offering is a direct consequence of two market developments: the broader tech weakness driven by the memory supply crisis, and the troubled IPO debut of SpaceX earlier in June, whose shares suffered heavy losses in the days following listing as global markets repriced risk.
OpenAI executives, who had targeted 2026 for a public offering, are now said to be evaluating a 2027 launch—giving markets time to stabilize and giving the company time to demonstrate that its AI infrastructure economics are sustainable at the scale that a public market valuation would demand.
The Rotation That May Define the Rest of 2026
The most significant market dynamic emerging from the memory chip crisis is not the decline in any single stock but the rotation it is enabling. As the mega-cap AI trade faces margin headwinds, investors are moving into financial and industrial companies, healthcare, and energy—sectors that had been overshadowed for years by the AI growth narrative. The Dow, weighted toward those steadier names, was holding up even as the Nasdaq declined through the final week of June.
That divergence—Dow up, Nasdaq down—is a familiar pattern in sector rotation cycles. It does not necessarily signal a bear market. It may signal the beginning of a more broadly distributed bull market, one less concentrated in five or seven names. The memory supply crisis, in that reading, is not the end of the AI boom—it is the first serious test of whether the boom’s economics are durable enough to survive contact with physical constraints.
Discover more from The Economy
Subscribe to get the latest posts sent to your email.
Analysis
US $39 Trillion National Debt 2026: Bond Market Warning Signs Explained
US national debt has crossed $39 trillion, bond yields are spiking, and Treasury auctions are showing soft demand. Here is what the bond market knows that Washington refuses to acknowledge.The United States crossed a number this year that no country in history has ever reached: $39 trillion in total federal debt. Not in inflation-adjusted terms. Not as a percentage of GDP. In raw dollars, the figure that sits on the public ledger of the world’s largest economy grew by $1 trillion in five months and $2 trillion in seven and a half months—and it is not slowing down.
What makes the velocity of that accumulation remarkable is the context in which it occurred. The Iran war added direct military expenditure at a pace that budget analysts said was accelerating. The 2025 tax cuts continued to erode revenue. And rising interest rates—the same rates the Federal Reserve is now signaling it may push higher still—are compounding the cost of servicing all that outstanding debt in a feedback loop that the bond market has quietly begun to price.
What the Auctions Are Saying
The most direct readout of market confidence in U.S. fiscal sustainability is the Treasury auction market, where the government sells new debt every week. Recent auctions have produced signals that bond investors usually describe in muted, technical language—but the direction is consistent.
A recent three-year Treasury auction cleared at 4.192%, well above the 3.965% at the prior auction. Yields rise when demand is soft. Soft demand at U.S. Treasury auctions is not a crisis signal—these are still among the most liquid securities in the world—but the trend line is one that fixed-income analysts at institutions ranging from J.P. Morgan to the Council on Foreign Relations have flagged as requiring close attention.
Foreign investors currently hold just above 30% of the Treasury market. Alarm bells rang briefly after April 2025’s Liberation Day tariffs—when U.S. bonds, equities, and the dollar all sold off together, the rarest of Wall Street trifectas—but subsequent data showed no dramatic reallocation away from Treasuries by foreign holders. That relative stability, however, depends on the continuation of conditions (a strong dollar, a functioning petrodollar system, geopolitical faith in U.S. institutions) that several of those conditions’ own architects now question.
The Interest Payment Problem
Of that $39 trillion, roughly $31.4 trillion is held by the public—the portion traded in financial markets globally. At current yields, the annual interest cost the U.S. government pays is on track to exceed $1 trillion for the first time in the country’s history. That figure is not a forecast. It is an arithmetic consequence of the debt level and the rate environment.
For context: U.S. defense spending in 2026 is approximately $900 billion. The federal government will spend more on interest payments than on the entire military. More than on Medicaid. More than on all discretionary non-defense programs combined. That structural reality constrains fiscal policy in ways that economists at the Deloitte Center for Financial Services have described as the most significant long-term challenge facing the U.S. economy.
“Higher bond yields affect U.S. fiscal dynamics in a number of ways,” analysts at the Council on Foreign Relations noted in their examination of tariff and Treasury interactions. “As interest payments on debt increase and use a greater share of available government funds, policymakers become more constrained around other fiscal priorities. They also can be more challenged when they need to respond to economic shocks.”
Three Credit Downgrades, Zero Course Correction
The United States has now been downgraded by all three major credit ratings agencies: S&P in 2011, Fitch in 2023, and Moody’s in May 2025. Each downgrade arrived with similar language—concerns about fiscal trajectory, political dysfunction over the debt ceiling, and a structural unwillingness to match revenues with spending. Each was followed by a brief market convulsion and then, effectively, nothing. Congress did not respond. The debt continued growing.
That pattern—of consequences being absorbed rather than heeded—is what makes the current moment structurally different from prior debt discussions, according to analysts who study sovereign fiscal crises. In those prior episodes, the U.S. still had room to maneuver: rates were low, the global appetite for dollar-denominated safe assets was rising, and alternative reserve currencies were even less credible than they are today. The margin for error has narrowed on all three dimensions.
The Political Ceiling on Solutions
The challenge is not primarily economic—it is political. Addressing a $39 trillion debt requires some combination of higher revenues, lower spending, or both. In the current Washington environment, tax increases are politically radioactive for one party and spending cuts face equivalent resistance from the other—particularly for the entitlement programs (Social Security, Medicare, Medicaid) that account for the largest share of mandatory outlays.
Markets have not yet priced the national debt as an immediate crisis, as analysts at U.S. Bank noted in their midyear market review: investors continue to watch whether rising debt eventually requires higher interest rates to attract enough Treasury buyers. The passive construction of that sentence—”continue to watch”—captures the market’s posture precisely. It is waiting. It is not yet acting.
The bond market’s message, in the language of Treasury yields and auction results, is being sent in increments rather than in a single shock. Washington is not listening. The question is not whether the message will eventually become impossible to ignore—it is how high rates must rise, and how much growth must slow, before the political system treats the ledger as a constraint rather than an abstraction.
Discover more from The Economy
Subscribe to get the latest posts sent to your email.
Analysis
Kevin Warsh Fed Rate Hike 2026: What His Hawkish Pivot Means for Markets
New Fed Chair Kevin Warsh surprised markets with a hawkish stance at his first FOMC press conference. Here’s how his rate-hike signals are rippling through stocks, bonds, mortgages, and gold. The Federal Reserve’s first policy meeting under new Chair Kevin Warsh sent shockwaves through global financial markets on June 17, 2026—not because policymakers moved rates, but because of what nine of them signaled they might do next.
Warsh, appointed by President Trump after months of public attacks on his predecessor Jerome Powell, arrived in Washington carrying expectations of a dovish turn. He had championed rate reductions while angling for the chairmanship, and the White House broadly supported looser monetary conditions. What markets got instead was a coldly hawkish institution that spent the better part of two hours dismantling those assumptions in real time.
The Meeting That Changed the Calculus
The Federal Open Market Committee held the federal funds rate unchanged at its existing range, but nine of 18 committee members penciled in at least one rate hike before year-end in the central bank’s updated Summary of Economic Projections—the dot plot. Six of those nine indicated support for two quarter-point increases. The shift represented a dramatic departure from the March projections, in which no policymaker had envisioned a hike, and the committee as a whole had forecast one cut.
The Dow Jones Industrial Average fell 507 points, or 0.98%, in the session. The S&P 500 lost 1.21% and the Nasdaq Composite dropped 1.34%. Two-year Treasury yields—the instrument most sensitive to near-term rate expectations—jumped 16 basis points to 4.21%, their highest reading in more than a year. Traders scrambled to reprice Fed futures, with CME FedWatch data showing the probability of a September hike jumping to 49% from 27% the previous session.
Warsh’s Statement Was Deliberately Brief—and Deliberately Alarming
The published FOMC statement was unusually short. Warsh stripped language that had previously signaled the Fed’s next move would be a cut and replaced it with a blunt acknowledgment that inflation remains “elevated”—a legacy partly of energy “supply shocks” stemming from the conflict in the Middle East.
“We’ve missed on inflation for five years and we’re going to fix that,” Warsh told reporters. “When we deliver on our price stability objectives—which we will—the American people will feel as though the hardships they’ve been living through are in the rear-view mirror.”
U.S. inflation hit 4.2%—double the Fed’s 2% target and its highest level in three years—leaving the committee little political room to stay passive. Warsh declined to submit a personal rate forecast to the dot plot, an unusual act of institutional reticence that some analysts read as an attempt to preserve maximum flexibility.
Bank of America Changes Its Forecast
Within days, Bank of America overhauled its rate outlook. Analysts at the bank predicted the Fed would raise the benchmark rate by a quarter point three times in 2026, lifting it from the current 3.5%–3.75% range to 4.25%–4.5%. The bank’s prior base case had been for rates to hold steady all year.
“The risk that they might need to raise rates has clearly risen,” said Matthew Luzzetti, chief U.S. economist at Deutsche Bank. BofA analysts acknowledged that Warsh could still be “strategically hawkish”—gaining anti-inflation credibility while actually buying time to cut later—but said the door to that interpretation was closing as incoming data showed persistent price pressure.
The hawkish turn unfolded against an unusual institutional backdrop. Warsh became the first new Fed chairman in more than 70 years to inherit an active predecessor on the governing board. Powell, whose term as chair Warsh replaced, remained as a board governor and voted at the June meeting—a fact that gives every subsequent public utterance from the former chair a level of market weight that Warsh’s team cannot easily ignore.
The Housing Market Reads a New Era
The rate signals carried immediate consequences for American homebuyers. Chen Zhao, head of economics research at Redfin, called it “a new era” and warned that mortgage rates were unlikely to retreat significantly in the near term. Bill Banfield of Rocket Mortgage noted that home sales were responding more to labor market strength than to rate movements and that determined buyers would continue entering the market—though the affordability calculus had shifted.
Vishal Garg, CEO of AI mortgage platform Better, cut to the practical point: “The Fed doesn’t set mortgage rates, but mortgage rates track long-term Treasury yields, which move based on investor expectations for inflation, growth, and the Fed’s next step.”
Warsh has separately announced five internal task forces to examine the Fed’s communication practices, data sources, and inflation-analysis frameworks—a structural reform effort that signals he intends a longer-term overhaul of the institution rather than a cosmetic change of tone.
What Comes Next
The path forward for markets hinges on three variables: whether consumer prices moderate fast enough to make hikes unnecessary, whether the labor market stays strong enough to absorb higher borrowing costs, and whether Warsh can maintain independence from a White House that publicly installed him to cut.
Kristina Hooper, chief market strategist at Man Group, summed up the market’s posture after the meeting: “Markets were holding out hope that Chair Warsh would throw them some kernels of real dovishness that they obviously felt they didn’t get.”
With BofA now projecting a rate corridor that would be the highest since 2007, and with inflation stubbornly running at twice the Fed’s target, the calculation Warsh faces is one no new Fed chair has confronted in a generation: tighten into a White House headwind or validate exactly the critics who warned his appointment was political.
Discover more from The Economy
Subscribe to get the latest posts sent to your email.
-
Markets & Finance6 months agoTop 15 Stocks for Investment in 2026 in PSX: Your Complete Guide to Pakistan’s Best Investment Opportunities
-
Analysis4 months agoTop 10 Stocks for Investment in PSX for Quick Returns in 2026
-
Analysis5 months agoBrazil’s Rare Earth Race: US, EU, and China Compete for Critical Minerals as Tensions Rise
-
Analysis4 months agoJohor’s Investment Boom: The Hidden Costs Behind Malaysia’s Most Ambitious Economic Surge
-
Banks5 months agoBest Investments in Pakistan 2026: Top 10 Low-Price Shares and Long-Term Picks for the PSX
-
Investment6 months agoTop 10 Mutual Fund Managers in Pakistan for Investment in 2026: A Comprehensive Guide for Optimal Returns
-
Global Economy6 months ago15 Most Lucrative Sectors for Investment in Pakistan: A 2025 Data-Driven Analysis
-
Global Economy6 months agoPakistan’s Export Goldmine: 10 Game-Changing Markets Where Pakistani Businesses Are Winning Big in 2025
